Tag Archives: Metformin

A new ICU study links prior metformin use to lower odds of acute kidney injury. Explore the findings, limitations, and implications for diabetes care.

A small 84-day trial found greater A1C and BMI improvements with a high-fiber diet than metformin. Explore the results, limitations, and clinical implications.

Metformin B12 deficiency can cause numbness that resembles diabetic neuropathy. Learn who is at risk, when to test B12, and why early detection matters.

Discover what 378 trials involving 113,000+ participants reveal about prediabetes treatment, lifestyle changes, metformin, and incretin therapies.

Could a stool sample someday help clinicians choose a diabetes medication before writing the prescription? Emerging research into gut biomarkers in diabetes is moving that possibility closer to clinical reality. Rather than simply cataloging which bacteria live in the intestine, researchers are examining microbial genes, stool-derived metabolites, and functional signatures …

Imagine prescribing the same diabetes medication to two patients with nearly identical A1C levels, only to see one achieve excellent glycemic control while the other experiences little benefit or troublesome side effects. This scenario is common in diabetes care and highlights an important question: could genetics explain these differences? Growing …

Young adults diagnosed with type 2 diabetes early in life often face a more aggressive disease course than older adults. While metformin has long served as the standard first-line therapy, many clinicians are now reconsidering whether a “metformin-first and wait” strategy is enough for this higher-risk population. As research continues …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …

Managing type 2 diabetes today can feel like solving a moving puzzle. With so many therapies available, how do clinicians decide what comes next? GLP-1 therapies have become a key part of today’s diabetes treatment algorithm, helping providers balance glucose control, cardiovascular risk, and patient preferences. As treatment options evolve, …

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …